Abstract:Despite the devastating clinical outcome of the neurodegenerative disease, amyotrophic lateral sclerosis (ALS), its etiology remains mysterious. Approximately 90% of ALS is characterized as sporadic, signifying that the patient has no family history of the disease. The development of an impactful disease modifying therapy across the ALS spectrum has remained out of grasp, largely due to the poorly understood mechanisms of disease onset and progression. Currently, ALS is invariably fatal and rapidly progressive. It is hypothesized that multiple factors can lead to the development of ALS, however, treatments are often focused on targeting specific familial forms of the disease (10% of total cases). There is a strong need to develop disease modifying treatments for ALS that can be effective across the full ALS spectrum of familial and sporadic cases. Although the onset of disease varies significantly between patients, there are general disease mechanisms and progressions that can be seen broadly across ALS patients. Therefore, this review explores the targeting of these widespread disease mechanisms as possible areas for therapeutic intervention to treat ALS broadly. In particular, this review will focus on targeting mechanisms of defective protein homeostasis and RNA processing, which are both increasingly recognized as design principles of ALS pathogenesis. Additionally, this review will explore the benefits of gene therapy as an approach to treating ALS, specifically focusing on the use of adeno-associated virus (AAV) as a vector for gene delivery to the CNS and recent advances in the field.

Molecular and Cellular Mechanisms Affected in ALS

Research Progress on Vesicular Trafficking in Amyotrophic Lateral Sclerosis.

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

The genetics and neuropathology of amyotrophic lateral sclerosis

Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis

Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis

Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors

Amyotrophic Lateral Sclerosis (ALS): An Overview of Genetic and Metabolic Signaling Mechanisms

Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis

The Current Potential Pathogenesis of Amyotrophic Lateral Sclerosis

Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights

Decoding ALS: from genes to mechanism

Multiple ways to a dead end: diverse mechanisms by which ALS mutant genes induce cell death

Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Old versus New Mechanisms in the Pathogenesis of ALS

Amyotrophic lateral sclerosis: translating genetic discoveries into therapies

Novel therapeutic targets for amyotrophic lateral sclerosis: ribonucleoproteins and cellular autonomy